Combination treatment of arthritic disease
US12303489B2 · kind B2 · utility
0Cited by
12References
18Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | May 7, 2020 |
| Grant date | May 20, 2025 |
| Priority date | — |
| Expiry date | Jun 15, 2042 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K9/0053
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to a composition comprising, separately or together, methotrexate (MTX) and (E)-N-trans-{3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-allylidene}-aminoguanidinium acetate (AP1189), or pharmaceutically acceptable derivatives thereof, for use in a method of treating an arthritis disease, such as rheumatoid arthritis.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.